Bio-Technopark Schlieren-Zürich
8952 Schlieren, Wagistrasse 23
+41 76 336 99 44
mario.jenni@bio-technopark.ch
The Bio-Technopark offers professional support for life science start-ups in the setting up and expansion of business activities and promotes interaction between start-ups, academia and industry. A nationally and internationally respected science park has grown up at Schlieren. Through stringent selection, coaching and support, more than 30 successful start-up companies with 750 employees are located here. Eight have been acquired by large corporates, but are still active in the park. Together with 20 institutes and clinics from the University and University Hospital Zurich, an innovative mix of very young and well-established companies and academic research groups has emerged.
Bio-Technopark Schlieren-Zürich
Wagistrasse 23
8952 Schlieren
11 Ergebnisse für "acquired" unter Bio-Technopark Schlieren-Zürich
Proteomedix acquired by Blue Water Biotech to form Onconetix Inc., ...
... News Proteomedix acquired by Blue Water Biotech to form Onconetix Inc., a commercial stage men’s ... announced it has been acquired by US-based, NASDAQ-listed Blue Water Biotech Inc. (NASDAQ: BWV) in a share ... Proteomedix acquired by Blue Water Biotech to form Onconetix Inc., a commercial stage men’s health ... https://www.bio-technopark.ch/en/news-en/proteomedix- acquired-by-blue-water-biotech-to-form ... Proteomedix acquired by Blue Water Biotech to form Onconetix Inc., a commercial stage men’s health ...
Somagenetix
https://www.wysszurich.ch/projects/somagenetix
8952 Schlieren, Wagistrasse 23
Gene therapy solutions for patients with severe inherited diseases.
Somagenetix
Wagistrasse 23
8952 Schlieren
896 Ergebnisse für "acquired" unter Somagenetix
Idiopathic non-histaminergic acquired angioedema: a case series and...
... Copy Abstract BACKGROUND: Idiopathic non-histaminergic acquired angioedema (InH-AAE) is a rare ... . Retrospectively registered 24.11.2016. Abstract BACKGROUND: Idiopathic non-histaminergic acquired angioedema ... Idiopathic non-histaminergic acquired angioedema: a case series and discussion of published ... Idiopathic non-histaminergic acquired angioedema: a case series and discussion of published ... Idiopathic non-histaminergic acquired angioedema: a case series and discussion of published ...
Structural aspects of molecular recognition in the immune system. P...
... immune system. Part I: Acquired immunity (IUPAC Technical Report). Pure and Applied Chemistry, 86(10 ... Structural aspects of molecular recognition in the immune system. Part I: Acquired immunity (IUPAC ... Structural aspects of molecular recognition in the immune system. Part I: Acquired immunity (IUPAC ... Structural aspects of molecular recognition in the immune system. Part I: Acquired immunity (IUPAC ...
Molecular Partners AG
http://www.molecularpartners.com
8952 Schlieren, Wagistrasse 14
+41 44 755 77 00
Molecular Partners AG is a clinical-stage biopharmaceutical company, located in Schlieren, Switzerland, that is developing a new class of therapies known as DARPin® therapies.
Molecular Partners AG
Wagistrasse 14
8952 Schlieren
14 Ergebnisse für "acquired" unter Molecular Partners AG
BVF Partners L.P., a US-based investor focused on biotechnology inv...
... -investments- acquired-shares-from-pre-ipo-venture-capital-shareholders/ ... BVF Partners L.P., a US-based investor focused on biotechnology investments, acquired shares from ... BVF Partners L.P., a US-based investor focused on biotechnology investments, acquired shares from ...
Comments on: BVF Partners L.P., a US-based investor focused on biot...
... Comments on: BVF Partners L.P., a US-based investor focused on biotechnology investments, acquired ... focused on biotechnology investments, acquired shares from pre-IPO venture capital shareholders Building ... Comments on: BVF Partners L.P., a US-based investor focused on biotechnology investments, acquired ... -investments- acquired-shares-from-pre-ipo-venture-capital-shareholders/feed/ ... Comments on: BVF Partners L.P., a US-based investor focused on biotechnology investments, acquired ...
University of Zurich
https://www.campus-schlieren.uzh.ch/en.html
8952 Schlieren, Wagistrasse 12
The University of Zurich (UZH) is Switzerland’s largest university, with seven faculties and a current enrollment of over 26,000 students. More than 5,000 highly qualified members of the teaching staff, including some 580 professors, teach and conduct research at the 150 University institutes. In the field of life sciences, the University of Zurich is well known for its groundbreaking research in medicine, immunology, neuroscience, and structural biology. In the interest of serving the community, the University of Zurich promotes the transfer of research-based knowledge to private enterprise, and our spin-off ventures and business partnerships regularly lead to the creation of attractive jobs in innovative fields.
University of Zurich
Wagistrasse 12
8952 Schlieren
1292 Ergebnisse für "acquired" unter University of Zurich
Evaluation of spectrodirectional alfalfa canopy data acquired durin...
... Evaluation of spectrodirectional alfalfa canopy data acquired during DAISEX'99 - Geoscience and ... . 5, MAY 2003 Evaluation of Spectrodirectional Alfalfa Canopy Data Acquired During DAISEX’99 Gabriela ... Evaluation of spectrodirectional alfalfa canopy data acquired during DAISEX'99 - Geoscience and ... Evaluation of spectrodirectional alfalfa canopy data acquired during DAISEX'99 - Geoscience and ... Evaluation of spectrodirectional alfalfa canopy data acquired during DAISEX'99 - Geoscience and ...
First report of naturally acquired clinical sarcocystosis in a pig ...
... First report of naturally acquired clinical sarcocystosis in a pig breeding stock Copy Abstract A ... First report of naturally acquired clinical sarcocystosis in a pig breeding stock - Zurich Open ... First report of naturally acquired clinical sarcocystosis in a pig breeding stock - Zurich Open ... First report of naturally acquired clinical sarcocystosis in a pig breeding stock - Zurich Open ...
LimmaTech Biologics AG
8952 Schlieren, Grabenstrasse 3
+41 44 733 85 85
info@lmtbio.com
LimmaTech Biologics AG is a clinical stage biopharmaceutical company focused on the development and manufacture of next generation bioconjugate vaccines using glycoengineering and protein glycosylation techniques previously developed by GlycoVaxyn and now owned by GSK. It was founded as a spin-off of GlycoVaxyn AG, which was acquired by GSK in February 2015 following a two-year collaboration. LimmaTech is developing vaccines exclusively for GSK and actively explores applications of glycoengineering and protein glycosylation technology in other fields.
LimmaTech Biologics AG
Grabenstrasse 3
8952 Schlieren
5 Ergebnisse für "acquired" unter LimmaTech Biologics AG
Board of Directors | LimmaTech Biologics AG
... Pharmaceuticals, which were acquired by GlaxoSmithKline and Chiron, respectively. He served as the Global ... and member of the Board of Directors of GlycoVaxyn for seven years. GlycoVaxyn was acquired by GSK in ... Biomedical and PowderJect Pharmaceuticals, which were acquired by GlaxoSmithKline and Chiron, respectively ... . GlycoVaxyn was acquired by GSK in February 2015. From 2004 to 2007, he was chairman and Chief Executive ...
Roche Glycart AG
https://www.roche.ch/en/sites/schlieren
8952 Schlieren, Wagistrasse 10
+41 43 215 10 00
The mission of the Roche Innovation Center Zurich (RICZ) is to be a leader in developing new generations of engineered antibody products with increased efficacy that address unmet clinical needs. The RICZ site is also the Center of Excellence in Cancer Immunotherapy within the Roche Group.
Roche Glycart AG
Wagistrasse 10
8952 Schlieren
105 Ergebnisse für "acquired" unter Roche Glycart AG
Roche | Roche Venture Fund Portfolio
... Ambrx ( acquired by Wuxi) Artus ( acquired by Qiagen) Avexis ( acquired by Novartis) BioFire ( acquired ... by bioMérieux) BioXell ( acquired by Cosmo) CGI ( acquired by Gilead) DVS ( acquired by Fluidigm) Envoy ... Portfolio Vaxcyte Vivet Therapeutics Exits via M&A M&A Afferent ( acquired by Merck) Alios ( acquired by ... Johnson+Johnson) Ambit ( acquired by Daiichi Sankyo) Ambrx ( acquired by Wuxi) Artus ( acquired by Qiagen ...
ETH Entrepreneurship
https://ethz.ch/en/industry/entrepreneurship.html
8952 Schlieren, Wagistrasse 18
Excellence in entrepreneurship at ETH Zurich is driven by world-class research and education. It gives rise to groundbreaking new ventures that consolidate Switzerland’s technological leadership. Are you an aspiring entrepreneur seeking to find solutions to global challenges and create a better future for humanity. Or are you just interested in the entrepreneurial ecosystem at ETH Zurich? Browse our websites to find out more or reach out to the Entrepreneurship group, if you have any questions.
ETH Entrepreneurship
Wagistrasse 18
8952 Schlieren
448 Ergebnisse für "acquired" unter ETH Entrepreneurship
Letters From a Stoic – Xenotheka
... From a Stoic The power and wealth which Seneca the Younger (c.4 B.C. – A.D. 65) acquired as ... From a Stoic The power and wealth which Seneca the Younger (c.4 B.C. – A.D. 65) acquired as ...
Stoic philosophy – Xenotheka
... Stoic The power and wealth which Seneca the Younger (c.4 B.C. – A.D. 65) acquired as Nero’ ... Stoic The power and wealth which Seneca the Younger (c.4 B.C. – A.D. 65) acquired as Nero’ ...
Neurimmune Therapeutics AG
8952 Schlieren, Wagistrasse 18
+41 44 755 46 46
info@neurimmune.com
Neurimmune is a biopharmaceutical company dedicated to the development of immunotherapeutics for the treatment and prevention of human disorders with a focus on protein aggregation diseases.
Neurimmune Therapeutics AG
Wagistrasse 18
8952 Schlieren
16 Ergebnisse für "acquired" unter Neurimmune Therapeutics AG
Neurimmune - 03.02.2016: BIIB076 (anti-tau mAb) moving into pre-IND...
... target that is believed to play a central role in Alzheimer's disease. Biogen acquired Neurimmune’s anti ... . Biogen acquired Neurimmune’s anti-tau program NI-105 in 2010, together with its anti-alpha-synuclein ...
Neurimmune - 19.02.2017: BIIB076 Moves into Phase 1 for Alzheimer's...
... antibody targeting tau, was discovered by Neurimmune and acquired by Biogen in 2010. The clinical trial ... recombinant monoclonal antibody targeting tau, was discovered by Neurimmune and acquired by Biogen in 2010 ...
CSL Vifor
https://www.csl.com/we-are-csl/our-businesses-and-products/csl-vifor
8952 Schlieren, Wagistrasse 25
+41 58 851 80 00
Pioneer in iron-based therapies, CSL Vifor is a global leader in iron deficiency and iron deficiency anaemia therapies, with a history dating back to 1872, when pharmacist Caspar Friedrich Hausmann opened a pharmacy in St. Gallen, Switzerland. Since then, we have proven our ability to identify and serve therapeutic areas and patients with significant unmet medical need. Building on our heritage and expertise in iron deficiency therapy, and together with our joint company Vifor Fresenius Medical Care Renal Pharma, today we have a strong and rapidly growing presence in nephrology, and we are committed to launching the next generation of therapies to truly address the full spectrum of kidney disease.
CSL Vifor
Wagistrasse 25
8952 Schlieren
38 Ergebnisse für "acquired" unter CSL Vifor
CSL Annual Report 2023 – Page 123
... and paid $11,665m for 100% of CSL Vifor shares (includes shares acquired in the prior year ended 30 ... accounting in accordance with AASB 3 ‘Business Combinations’ and consequently the CSL Vifor assets acquired ... acquired in the prior year ended 30 June 2022). The Group delisted Vifor Pharma Ltd from the Swiss Stock ... consequently the CSL Vifor assets acquired, and liabilities assumed, have been recorded at fair value, with any ...
CSL Annual Report 2023 – Page 122
... expenditure excludes PPE and intangible assets acquired in connection with the acquisition of CSL Vifor (Note ... ) amortisation of acquired IP (commercialised) of which $181m is attributable to CSL Limited shareholders (2022 ... underlying results 9 Capital expenditure excludes PPE and intangible assets acquired in connection with the ... (2022: $2m) amortisation of acquired IP (commercialised) of which $181m is attributable to CSL Limited ...
University Hospital Zurich, Research and Education Office
https://www.usz.ch/forschung/Seiten/default.aspx
8091 Zürich, Rämistrasse 100
The University Hospital Zurich is one of Switzerland’s largest hospitals and a pioneering institution in the field of clinical research. In its 40 departments and institutes, it assembles and practices all medical disciplines and enjoys an excellent reputation for state-of-the-art medicine, professional and com- passionate patient care, and groundbreaking bench-to-bedside translational medical research.
University Hospital Zurich, Research and Education Office
Rämistrasse 100
8091 Zürich
131 Ergebnisse für "acquired" unter University Hospital Zurich, Research and Education Office
Slide A III 11b
... acquired while the fetus is still in the womb. ... period. Multiple fractures are acquired while the fetus is still in the womb. ...